MannKind Corporation filed a current report on August 21, 2026, disclosing the submission of a prospectus supplement to its automatic shelf registration statement and attaching a legal opinion from Cooley LLP regarding the legality of the issuance and sale of common stock.

Key Highlights

  • Prospectus Supplement Filed: MannKind filed a prospectus supplement to its automatic shelf registration statement on Form S-3, Registration No. 333-285286, with the SEC on August 21, 2026.
  • Legal Opinion Attached: The filing includes an opinion from Cooley LLP, filed as Exhibit 5.1, relating to the legality of the issuance and sale of shares of common stock set forth in the prospectus supplement.
  • Common Stock Details: MannKind's common stock has a par value of $0.01 per share and is listed on NASDAQ:MNKD.
  • Signed by General Counsel: The report was signed by David Thomson, Ph.D., J.D., Executive Vice President, General Counsel and Secretary of MannKind Corporation.
  • No Emerging Growth Company: MannKind indicated in the filing that it does not qualify as an emerging growth company.

MannKind Corporation Registers Common Stock Shares Under Shelf Offering

MannKind Corporation, a Delaware-incorporated biopharmaceutical company headquartered at 1 Casper Street, Danbury, Connecticut, filed a current report under Item 8.01 (Other Events) on August 21, 2026. According to the filing, the company submitted a prospectus supplement to its existing automatic shelf registration statement on Form S-3, bearing Registration No. 333-285286, with the U.S. Securities and Exchange Commission. The filing was made in connection with the issuance and sale of shares of MannKind's common stock, par value $0.01 per share, as described in the prospectus supplement.

The company disclosed that the primary purpose of this current report was to file the legal opinion of Cooley LLP, attached as Exhibit 5.1, addressing the legality of the common stock issuance and sale referenced in the prospectus supplement. Cooley LLP's consent, incorporated within Exhibit 5.1, was also filed as Exhibit 23.1. The filing noted that MannKind's common stock trades on The Nasdaq Stock Market LLC under the symbol MNKD, and that the company is incorporated in Delaware with Commission File Number 000-50865.

The report was authorized and signed on behalf of MannKind Corporation by David Thomson, Ph.D., J.D., in his capacity as Executive Vice President, General Counsel and Secretary, as of August 21, 2026. The filing did not disclose the specific number of shares or pricing terms associated with the prospectus supplement, as those details reside in the prospectus supplement itself rather than in this current report.

What Was Disclosed

MannKind Corporation disclosed the filing of a prospectus supplement to a Form S-3 shelf registration and attached Cooley LLP's legal opinion on the legality of the related common stock issuance. The report was filed under Item 8.01 on August 21, 2026.